Evidence map›Paper›PMID 41432933›Full record

ArticleCancer immunology, immunotherapy : CII2025

Multi-omics profiling reveals an immunosuppressive plasma cell subset within tertiary lymphoid structures in cervical cancer.

Qingyu Huang, Fuhao Wang, Xiaohui Li, Wenxue Zou, Zhou Huang, Xia Li, Wenhui Yang, Tianyu Lei, Shengqin Yue, Qian Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qingyu Huang *Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Fuhao Wang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Xiaohui Li *Department of Medical Oncology, Peking University First Hospital, Beijing, 100034, China.
Wenxue Zou *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Zhou Huang *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xia LiDepartment of Obstetrics and Gynecology, Heze Municipal Hospital, Heze, China.
Wenhui YangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Tianyu LeiDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Shengqin YueDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Qian WangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Qi AnDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Bicheng ZhangDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. bichengzhang@hotmail.com.
Cong WangDepartment of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. wangcongsdu@163.com.
Chao LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. charles.liu@whu.edu.cn.
Qinyong HuDepartment of Radiation Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China. 2925829838@qq.com.

Funding

Hubei Province Big Health Industry Development Special Fund 2019916000001National Natural Science Foundation of China 81670144National Natural Science Foundation of China 82403773Postdoctoral Fellowship Program of CPSF GZB20230041Special Project of Science and Technology Cooperation between Hubei Province and Chinese Academy of Sciences 42000021817T300000050Teaching research project of Medical Faculty of Wuhan University in 2021 2021026The Medical Education Research Project of the Medical Education Branch of Chinese Medical Association and Medical Education Professional Committee of Chinese Association of Higher Education 2020B-N15414
6 · The paper itself

Abstract

backgroundCervical cancer (CC) is a leading cause of cancer-related deaths in women, and understanding the tumor immune microenvironment is crucial for identifying novel biomarkers and therapeutic targets. While T cells have been extensively studied in oncology, the role of B cells in CC remains poorly understood.

methodsIn this study, we generated and integrated multi-omics data, including single-cell RNA sequencing, single-nucleus RNA sequencing, spatial transcriptomics, bulk RNA sequencing, and multiplex immunofluorescence to investigate the composition and transcriptomic states of B cells in CC.

resultsInitially, we analyzed plasma cells, classifying them into IgA

conclusionsWe identified distinct plasma cell subsets in CC and found that HSPA1B_PC are enriched in tumors, associated with immunosuppressive T cells in TLS. These findings suggest that HSPA1B_PC contribute to an immunosuppressive microenvironment in CC, highlighting their potential as therapeutic targets.

Indexed as

Plasma CellsTertiary Lymphoid StructuresUterine Cervical NeoplasmsFemaleHumansMultiomicsPrognosisSingle-Cell AnalysisTumor MicroenvironmentB cellCervical cancerMulti-omicsSingle-cell RNA sequencingTertiary lymphoid structure

Identifiers

PMID41432933
PMCPMC12728108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.